CA-NETAPP
1.12.2021 14:02:14 CET | Business Wire | Press release
NetApp® (NASDAQ: NTAP), a global, cloud-led, data-centric software company, today announced new innovations in its product portfolio as well as award recognition from Amazon Web Services (AWS) for its achievements as an AWS Partner. Together, these announcements demonstrate how NetApp's investments and vision are enabling any organization using AWS to access world-class cloud operations (CloudOps) and maximize the value of their investment.
At AWS re:Invent this week, NetApp was named the 2021 AWS Independent Software Vendor (ISV) Design Partner of the Year - US, for the jointly engineered and natively integrated Amazon FSx for NetApp ONTAP service. This fully-managed, multi-protocol storage service from AWS allows organizations to extend on-premises data onto AWS for enhanced data protection, migrate enterprise workloads without refactoring, and set the stage to run stateful Kubernetes applications. The award recognizes NetApp’s work in helping customers enable innovation and build solutions that drive digital and cloud transformation on the AWS Cloud.
“AWS Partners are critical to our customers’ success, and we are pleased to recognize NetApp as a 2021 AWS Partner of the Year US winner,” said Rachel Mushahwar, Head of Channel and Partner Sales - Americas, AWS. “I continue to be impressed by the commitment and innovation that NetApp offers our customers and how they are uniquely positioned to help accelerate our customers’ digital transformation journey. I look forward to working together and a great 2022.”
“We are proud to be named the AWS ISV Design Partner of the Year in the US," said Anthony Lye, Executive Vice President and General Manager of Public Cloud Services at NetApp. "For nearly a decade, NetApp and AWS engineers have worked together to create industry-leading cloud services, so it's incredibly exciting to see our joint innovation be recognized onstage at this year’s re:Invent. Together, NetApp and AWS are delivering the best of cloud to our customers and partners to deliver immediate business value, whether in the form of cost efficiency, compliance, data protection, or performance."
NetApp also announced important milestones in the growth of its Spot by NetApp product portfolio for CloudOps, including:
Spot Ocean for Apache Spark
Part of the Spot Ocean suite of products, Spot Ocean for Apache Spark combines the infrastructure automation and optimization of Spot Wave together with Data Mechanics, recently acquired by NetApp, to give data infrastructure teams the power and flexibility of Apache Spark on Kubernetes without the complexity of managing and tuning infrastructure and workloads. Ocean for Apache Spark
is now available in preview for AWS customers.
Spot Ocean Continuous Delivery (CD)
Also, part of the Spot Ocean suite, Spot Ocean CD extends Spot by NetApp’s core technologies with a solution for easy, reliable delivery of cloud-native applications on Kubernetes. Available for private preview with AWS customers in mid-December, Spot Ocean CD
makes it easy to quickly and reliably execute deployments with integrated and automated continuous verification to give developers full confidence in their deployments.
Together with Spot Ocean serverless infrastructure, these products make up the expanded Spot Ocean suite, bringing intelligent automation and optimization to cloud-native infrastructure and workloads on Kubernetes.
CloudCheckr Well-Architected Readiness Advisor
CloudCheckr, recently acquired by NetApp, complements the Spot product portfolio to expand Spot by NetApp’s financial operations (FinOps) capabilities. Spot by NetApp today announced the release of CloudCheckr Well-Architected Readiness Advisor, which helps managed service providers (MSPs) streamline the process of delivering AWS Well-Architected Reviews and helps to ensure that AWS customers are in compliance with the AWS Well-Architected Framework for optimization of cloud cost, security, operations, performance and reliability.
The Well-Architected Readiness Advisor is available on the CloudCheckr CMx platform.
Spot Security
Spot Security enables customers to quickly detect, prioritize and help mitigate the most serious security threats and risks within cloud infrastructure. Spot Security
is now available in private preview, starting with AWS customers.
“Getting applications to the cloud is only the first step in the cloud journey,” said Amiram Shachar, Vice President and General Manager of Spot by NetApp. “Realizing the promise of cloud requires a holistic approach to operating within the cloud, an approach that addresses cost, resource management, optimization and security. Our growing portfolio delivers a compelling suite of solutions for cloud operations that let organizations focus on their applications rather than on infrastructure.”
Additional Resources:
- Spot Ocean Suite Blog
- Spot Ocean for Apache Spark Blog
- CloudCheckr Well-Architected Readiness Advisor Blog
About NetApp
NetApp is a global, cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services and applications to the right people—anytime, anywhere. Learn more at www.netapp.com
or follow us on Twitter
, LinkedIn
, Facebook
, and Instagram
.
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211201005381/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
